outperform price
report solid broad revenu strength
biopharma fund remain intact manag note
 activ all-tim high top
robust industri fundament continu gain
share clinic market report mm
smart trial new rwe studi win busi
new client ta also continu deliv
expect manag laid merger
investor day oce notabl win
client far estim run rate revenu
road recoveri revenu guidanc also
came expect despit mm
coronaviru impact
may quibbl margin quarter
larg result continu technolog
invest across platform noth result
manag said call derail longer-
term ebitda growth algorithm given
consist execut see one best cro
rais pt
pleas see confer call note attach
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
china mm impact
fy expect segment
fx rate move lower expect mm
coronaviru impact primarili impact segment see disrupt hospit
bp contribut
ta revenu million million cc
 revenu expect mm mm
usual step
cc bp hw pass
 revenu growth expect lumpi specif relat
csm revenu growth improv though easi comp vs last management expect continu
four new larg pharma chosen oce new oce win win sinc roll full suit
avail end year start astrazeneca project soon
studyhub studi expand span multipl therapeut area inc oncolog dtx
rwe select prefer provid larg pharma client studi on-going
use non identifi genom data studi rwe
busi win new client prefer provid agreement top pharma client
top use smart trial approach mm dollar smart trial busi smart trial
oper patient
 fund all-tim high late stage pipelin grew outsourc penetr
grown almost vc fund remain robust record number deal
 backlog mm increas backlog expect becom revenu see
success emerg biotech client core power solut gain traction smart trial data
analyt wrap bid boost client win
mm cost manag initi save
offshor india eastern europ latam also expect continu
client use virtual trial doubl digitsmor less
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin februari
analyst elizabeth anderson luke sergott amato primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
